Hopp til innhold
NHI.no
Annonse

Nyrekreft, nyrecellekreft: Vil du vite mer?

Innhold i artikkelen

  • Nyrecellekreft - for helsepersonell
  • Ved behov for ytterligere råd eller veiledning, kontakt Kreftforeningen

Dette dokumentet er basert på det profesjonelle dokumentet Nyrekreft . Referanselisten for dette dokumentet vises nedenfor

  1. Shah AY. Renal cell carcinoma. BMJ Best Practice, last reviewed February 2020.
  2. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med nyrecellekreft. Helsedirektoratet 2015.
  3. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20. PMID: 30788497 PubMed
  4. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.
  5. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no.
  6. Motzer RJ, et al. Kidney cancer, version 2. 2017. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(6):804–834.
  7. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. Cancer stat facts: kidney and renal pelvis cancer. 2020 seer.cancer.gov
  8. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018; 36:1891-8. PMID: 29680948 PubMed
  9. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. PubMed
  10. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21(1):81–90.
  11. Peyromaure M, Misrai V, Thiounn N, et al. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004; 100: 1406-10. PubMed
  12. Cumberbatch MG, Rota M, Catto JW, La Vecchia C . The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.. Eur Urol 2016; 70: 458. pmid:26149669 PubMed
  13. Alanee S, Clemons J, Zahnd W, Sadowski D, Dynda D. Trichloroethylene is associated with kidney cancer mortality: a population-based analysis. Anticancer Res. 2015;35(7):4009–4013. PMID: 26124349. PubMed
  14. Capitano U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-84. pmid:30243799 PubMed
  15. Kompotiatis P, Thongprayoon C, Manohar S, et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology (Carlton). 2019; 24: 65-73. PMID: 29236344 PubMed
  16. Loo RK, Lieberman SF, Slezak JM, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc. 2013;88(2):129–138.
  17. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017 Sep;198(3):520-9. PMID: 28479239 PubMed
  18. Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019 Feb 1;99(3):179-184. PubMed
  19. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007; 356: 185-7. PMID: 17215538 PubMed
  20. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019 Mar;2(2):141-9. PMID: 31017089 PubMed
  21. US National Library of Medicine. ClinicalTrials.gov. A study of atezolizumab as adjuvant therapy in participants with renal cell carcinoma (RCC) at high risk of developing metastasis following nephrectomy . August 2020 clinicaltrials.gov
  22. Powles T, Albiges L, Staehler M et al. Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.. Eur Urol 2017. pmid:29223605 PubMed
  23. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008;34:183-192. PMID: 18061356 PubMed
  24. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-90. PubMed
  25. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-63. PubMed
Annonse
Annonse